Ribozymes in gene identification, target validation and drug discovery

Drug Discovery Today: TARGETS

Volumn 3, Issue 1, 2004, Pages 10-17

  Chatterton, Jon E ^a   Hu, Xiuyuan ^a   Wong Staal, Flossie ^a  

^a Immusol   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOZYME; SMALL INTERFERING RNA;

COMBINATORIAL LIBRARY; CORRELATION ANALYSIS; DRUG TARGETING; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE SEQUENCE; GENE SILENCING; GENOMICS; HUMAN; NONHUMAN; NUCLEIC ACID PROBE; PHENOTYPE; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; VALIDATION PROCESS;

EID: 1842484863     PISSN: 17418372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1741-8372(04)02382-5     Document Type: Review

References (60)

1. Bennett C.F., Cowsert L.M. Antisense oligonucleotides as a tool for gene functionalization and target validation. Biochim. Biophys. Acta. 1489:1999;19-30
2. Dean N.M. Functional genomics and target validation approaches using antisense oligonucleotide technology. Curr. Opin. Biotechnol. 12:2001;622-625
3. Paddison P.J., Hannon G.J. RNA interference: the new somatic cell genetics? Cancer Cell. 2:2002;17-23
4. Elbashir S.M., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:2001;494-498
5. Brummelkamp T.R., et al. A system for stable expression of short interfering RNAs in mammalian cells. Science. 296:2002;550-553
6. Paddison P.J., et al. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16:2002;948-958
7. James H.A., Gibson I. The therapeutic potential of ribozymes. Blood. 91:1998;371-382
8. Welch P.J., et al. Expression of ribozymes in gene transfer systems to modulate target RNA levels. Curr. Opin. Biotechnol. 9:1998;486-496
9. Hughes M.D., et al. The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov. Today. 6:2001;303-315
10. Bertrand E., et al. The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA. 3:1997;75-88
11. Koseki S., et al. Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III. J. Virol. 73:1999;1868-1877
12. Chang Z., et al. Enhanced expression and HIV-1 inhibition of chimeric tRNALys3-ribozymes under dual U6 snRNA and tRNA promoters. Mol. Ther. 6:2002;481-489
13. Kuwabara T., et al. Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: engineered tRNAs with an extended 3( end can be exported efficiently and specifically to the cytoplasm in mammalian cells. Nucleic Acids Res. 29:2001;2780-2788
14. Kawasaki H., et al. Identification of genes that function in the TNF-α-mediated apoptotic pathway using randomized hybrid ribozyme libraries. Nat. Biotechnol. 20:2002;376-380
15. Beger C., et al. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc. Natl. Acad. Sci. U. S. A. 98:2001;130-135
16. Li Q-X., et al. A novel functional genomics approach identifies mTERT as a suppressor of fibroblast transformation. Nucleic Acids Res. 28:2000;2605-2612
17. Welch P.J., et al. Identification and validation of a gene involved in anchorage-independent cell growth control using a library of randomized hairpin ribozymes. Genomics. 66:2000;274-283
18. Krüger M., et al. Identification of eIF2Bγ and eIF2γ as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach. Proc. Natl. Acad. Sci. U. S. A. 97:2000;8566-8571
19. Choi K.S., et al. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. Cancer Gene Ther. 10:2003;87-95
20. Macejak D.G., et al. Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo. J. Virol. 73:1999;7745-7751
21. Mathews D.H., et al. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structures. J. Mol. Biol. 288:1999;911-940
22. Scherr M., Rossi J.J. Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts. Nucleic Acids Res. 26:1998;5079-5085
23. Scherr M., et al. Oligonucleotide scanning of native mRNAs in extracts predicts intracellular ribozyme efficiency: ribozyme-mediated reduction of the murine DNA methyltransferase. Mol. Ther. 2:2000;26-38
24. Scherr M., et al. Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA. Mol. Ther. 4:2001;454-460
25. Pan W-H., et al. Rapid identification of efficient target cleavage sites using a hammerhead ribozyme library in an iterative manner. Mol. Ther. 7:2003;129-139
26. Kawasaki H., Taira K. Identification of genes by hybrid ribozymes that couple cleavage activity with the unwinding activity of an endogenous RNA helicase. EMBO Rep. 3:2002;443-450
27. Warashina M., et al. RNA-protein hybrid ribozymes that efficiently cleave any mRNA independently of the structure of the target RNA. Proc. Natl. Acad. Sci. U. S. A. 98:2001;5572-5577
28. Kuwabara T., et al. Cleavage of an inaccessible site by the maxizyme with two independent binding arms: an alternative approach to the recruitment of RNA helicases. J. Biochem. (Tokyo). 132:2002;149-155
29. Craig A.W., et al. Interaction of polyadenylate-binding protein with the eIF4G homologue PAIP enhances translation. Nature. 392:1998;520-523
30. Tang H., et al. A cellular cofactor for the constitutive transport element of type D retrovirus. Science. 276:1997;1412-1415
31. Shahi S., Banerjea A.C. Multitarget ribozyme against the S1 genome segment of reovirus possesses novel cleavage activities and is more efficacious than its constituent mono-ribozymes. Antiviral Res. 55:2002;129-140
32. Beigelman L., et al. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J. Biol. Chem. 270:1995;25702-25708
33. Zinnen S.P., et al. Selection, design, and characterization of a new potentially therapeutic ribozyme. RNA. 8:2002;214-228
34. Kurreck J., et al. Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I. J. Biol. Chem. 277:2002;7099-7107
35. Konopka K., et al. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim. Biophys. Acta. 1372:1998;55-68
36. Düzgünes N., et al. Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH-sensitive liposomes. Nucleosides Nucleotides Nucleic Acids. 20:2001;515-523
37. Michienzi A., et al. Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA. Proc. Natl. Acad. Sci. U. S. A. 97:2000;8955-8960
38. Lee N.S., et al. mRNA localization signals can enhance the intracellular effectiveness of hammerhead ribozymes. RNA. 5:1999;1200-1209
39. Castanotto D., et al. Intracellular ribozyme applications. Biochem. Soc. Trans. 30:2002;1140-1145
40. Orlandi L., et al. Ribozyme-mediated inhibition of PKCα sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis. Prostate. 54:2003;133-143
41. Collis S.J., et al. Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res. 29:2001;1534-1538
42. Tanaka M., et al. Impaired expression of a human septin family gene Bradeion inhibits the growth and tumorigenesis of colorectal cancer in vitro and in vivo. Cancer Gene Ther. 9:2002;483-488
43. Luo X., et al. Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme. Int. J. Cancer. 104:2003;716-721
44. Moscatello D.K., et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55:1995;5536-5539
45. Powers C., et al. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J. Biol. Chem. 277:2002;14153-14158
46. Jarvis T.C., et al. Ribozymes as tools for therapeutic target validation in arthritis. J. Immunol. 165:2000;493-498
47. Gervaix A., et al. Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J. Virol. 71:1997;3048-3053
48. Feng Y., et al. Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5. Virology. 276:2000;271-278
49. Rhoades K., Wong-Staal F. Inverse Genomics™ as a powerful tool to identify novel targets for the treatment of neurodegenerative diseases. Mech. Ageing Dev. 124:2003;125-132
50. Kawasaki H., Taira K. A functional gene discovery in the Fas-mediated pathway to apoptosis by analysis of transiently expressed randomized hybrid-ribozyme libraries. Nucleic Acids Res. 30:2002;3609-3614
51. Suyama E., et al. Identification of genes involved in cell invasion by using a library of randomized hybrid ribozymes. Proc. Natl. Acad. Sci. U. S. A. 100:2003;5616-5621
52. Suyama E., et al. Identification of genes responsible for cell migration by a library of randomized ribozymes. Cancer Res. 63:2003;119-124
53. Kinsella T.M., et al. Retrovirally delivered random cyclic peptide libraries yield inhibitors of interleukin-4 signaling in human. B cells. J. Biol. Chem. 277:2002;37512-37518
54. Miller V.M., et al. Allele-specific silencing of dominant disease genes. Proc. Natl. Acad. Sci. U. S. A. 100:2003;7195-7200
55. Grassi G., et al. Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects. Nucleic Acids Res. 25:1997;3451-3458
56. Jackson A.L., et al. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21:2003;635-637
57. Denman R.B. Hairpin ribozyme specificity in vivo: A case of promiscuous cleavage. Biochem. Biophys. Res. Commun. 257:1999;356-360
58. Sledz C.A., et al. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5:2003;834-839
59. Miyagishi M., et al. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev. 13:2003;1-7
60. Yelin R., et al. Widespread occurrence of antisense transcription in the human genome. Nat. Biotechnol. 21:2003;379-386